Equillium, Inc. ("Equillium" or the "Company") (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat ...

Equillium, Bluejay Diagnostics, and Entero Therapeutics are the 3 Penny Stocks to watch on August 12, 2025, based on TipRanks ...

Equillium stock is trading higher Monday after the company announced up to $50 million in financing through a securities ...

Shares in the chipmaker were higher in pre-market trading as US president Donald Trump signalled he was open to working with ...

LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet ...

Equillium, Inc., a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced ...

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host ...

Equillium is currently enrolling patients in a Phase 2 proof-of-concept study of EQ101 for patients with alopecia areata. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 ...

Access Equillium stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease Treatment with itolizumab did not improve complete ...

Equillium, Inc. and Metacrine Inc., today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock ...